Stock AnalizCigna Group CI
Medical Specialities · data as of November 13, 2026
Cigna Group (CI) is a healthcare company listed in the US with a market value of about $78.3B. In the twelve months to September 30, 2026 it had revenue of $286.3B and net income of $6.0B, a net margin of 2.1%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is shareholder returns (5/5); the weakest is track record (2/5).
Key numbers: a P/E of 13.1, a price to free cash flow of 9.5, 5-year revenue growth of 11% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% above the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
Checks not passed
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $286.3B | $274.9B | $247.1B | $195.3B | $180.5B | $174.1B | $160.4B | $153.6B | $48.6B | $41.8B | $39.8B |
| Net income | $6.0B | $6.0B | $3.4B | $5.2B | $6.7B | $5.4B | $8.5B | $5.1B | $2.6B | $2.2B | $1.9B |
| Free cash flow | $8.3B | — | — | — | — | — | — | $8.4B | $3.2B | $3.6B | $3.6B |
| EPS (diluted) | $22.68 | $22.18 | $12.12 | $17.39 | $21.41 | $15.75 | $22.96 | $13.44 | $10.54 | $8.77 | $7.19 |
| Net margin | 2.1% | 2.2% | 1.4% | 2.6% | 3.7% | 3.1% | 5.3% | 3.3% | 5.4% | 5.3% | 4.7% |
| ROIC | — | 10.2% | 9.2% | 10.7% | 8.9% | 7.8% | 7.6% | 7.5% | 3.8% | 12.8% | 13.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 25 analysts is $342.68, 15% above the current price; targets range from $288.00 to $400.00; the consensus rating is “Buy”; expected EPS is $30.62 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Cigna’s P/E ratio?
About 13.1, based on the last twelve months of diluted earnings per share (forward P/E about 9.2).
Is Cigna stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cigna pay a dividend?
Yes. The dividend yield is about 2.07%, and it has paid dividends for 10 years in our data.
Is Cigna a good stock to buy?
We do not give buy or sell advice. Cigna scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.